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ABSTRACT  
          A Cancer patients need long term therapy in the treatment 
of their disease. One of the outcome of cancer treatment in patients 
of quality of life. Because of the limited instrument for measuring 
cancer patients’ quality of life in Indonesian version, thus this study 
is aimed to develop the validation of Indonesian version of Short 
Form-36 questionnaire in cancer patients. The observational study 
was carried out in this study. Data were collected from cancer 
patients in the Oncology Department of  Sardjito Hospital, 
Yogyakarta, Indonesia, who were treated with cisplatin at the 
dosage of ≥ 50mg/m2 as monotherapy or in combinations. The 
validation process involved known-group validity, discriminant 
validity, convergent validity and factor analysis. About 203 subjects 
who were diagnosed with cancer were recruited in this study. The 
known-group validity test showed that there were no significant 
differences of SF-36 domains among different diagnosa. All of the 
questions met the criteria of convergent validity except for the 
questions number 26, 28, 30 and 32. Furthermore, the questions 
number 2 and 28 did not meet the criteria of discriminant validity. 
This study presents that many questions are needed to be 
reconstructed, due to the result of factor analysis which showed 
that those questions are loaded significantly with other domain’s 
questions. The development of Indonesian version of SF-36 scales 
in cancer disease is still less unstatisfactory. According to the result 
of this study, future study with new construction of questions in this 
version is still necessary. 
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INTRODUCTION 
In Indonesia, approximately 200.000 
people were diagnosed with cancer every year. 
Similar to the other Asia countries, the cervical 
cancer is the most diagnosed cancer as well in 
Indonesia (Female Cancer Program, 2012). 
According to the WHO, the mortality due to 
cancer in Indonesia approximately 1.000.000 
per year in 2008 (World Health Organisation, 
2012). Because of the cancer burden, the 
appropriate monitoring of treatment, following 
the appropriate treatment, should be implicated 
in the standard treatment of cancer in 
Indonesia. 
Cancer is one of the diseases which 
needed long term of treatment. Because of the 
therefore, patients’ quality of life should be 
considered as outcome of the therapy, 
especially in patients with palliative treatment to 
understand the benefit of treatment in specific 
setting (Chase et al., 2012). Even, patients’ 
quality of life are more often to be measured as 
outcomes in some clinical trials, but in 
Indonesia. The cancer patients’ quality of life 
should be considered as one of the outcome 
therapy, because many serious side effects of 
chemotherapy could give negative impact to the 
patients quality of life (Perwitasari et al., 2012). 
For example, nausea and vomiting are the most 
distressing side effect of chemotherapy in 
cancer patients therefore, patients refused to 
follow next cycle of treatment (Sussman, 1995). 
The nausea and vomiting were often under-
reported, because the delayed effect of 
chemotherapy presented after the patients went 
homes. To avoid this negative impact, health 
providers should give closed monitoring in 
patients’ quality of life. 
The availability of reliable and valid 
instruments for measuring the patients’ quality 
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of life are still limited in Indonesia. The specific 
instruments for cancer disease according to 
European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life 
Questionnaire with 30 items questions (QLQ 
C30) has          been available in Indonesian 
version (Perwitasari et al., 2011). The challenge 
of developing the generic instruments, such as, 
Short Formulary-36 (SF36) in Indonesian 
version, is still being opened. SF-36 is a 
multidimensional questionnaire which has been 
translated worldwide, validated in much 
number of populations and could be applied in 
health and pathologic conditions (Gale et al., 
2012, Scarpa et al., 2011, Xie et al., 2012). Thus 
this study is aimed to develop the validity of the 
SF-36 in Indonesian version. The forward-
backward translation and reliability procedures 
of the Indonesian version of SF-36 has been 
published in the previous study (Perwitasari et 
al., 2011). 
 
METHODOLOGY 
Subjects 
Subjects in this study were cancer 
patients in the Oncology Department of           
Dr Sardjito Hospital, Yogyakarta, Indonesia, 
who were treated with a cisplatin dosage ≥ 
50mg/m2 as monotherapy or in combined 
chemotherapy regimens. The subjecs aged ≥ 18 
years old with a Karnofsky Index ≥ 50% were 
included. This study included subjects who 
treated by  cisplatin because cisplatin is one of 
the cytotoxic agents which has a severe 
emetogenic effect and has a significant effect 
on patients’ quality of life.  
 
Data collection 
The demoghraphic data, such as: age, 
sex, education, diagnosa of cancer and subjects’  
Karnofsky Performance Status (KPS) were 
collected from their medical records.  The 
questionnaire were given to the subjects a few 
hours prior chemotherapy asministration. The 
study was approved by the local ethics 
committee of the Faculty of Medicine, Gadjah 
Mada University, Yogyakarta.  
 
Statistical analysis 
The demographic data was presented as 
descriptive data with means and standard 
deviations (SDs). The convergent and 
discriminant validity was revealed if the item-
domain correlation was ≥ 0.40, while the 
requirements for discriminant validity were 
satisfied if the value of correlation coefficients 
between the item and its own domain was 
higher than other domains. The sensitivity  
validity was evaluated based on different 
diagnoses using ANOVA-test. Factor analysis 
was used to extract factors quality of life in SF-
36. Kaiser-Meyer-Olkin (KMO) and Bartlett’s 
Test were tested to know whether the data 
were suitable for factor analysis. The loading 
criterion was set at less than 0.40 of absolute 
value (Awad et al., 2008, Fredheim et al., 2007, 
McPherson & Martin, 2012). 
 
RESULT AND DISCUSSION 
This study recruited two hundred and 
three cancer subjects in Dr. Sardjito Hospital 
Yogyakarta. Table I presents the subjects’ 
characteristics. Most of the subjects were 
female, with the mean average of 48.3 (SD= 
9.4) and the performance scale average is 82.3 
(SD=6.1). According to the female cancer 
organisation of Indonesia and Netherland, 
cervical cancer was found as the most 
diagnosed cancer in Indonesia for the recent 
that years. This study supported the data that 
subjects diagnosed with cervical cancer where 
aaroximately 60.1%. 
The known group validity or the 
sensitivity test is presented in Table 2. There 
are no significant differences among the 
different diagnosa (P>0.05). The score of 
physical function, has limited role because of 
the physical and emotional limitation, social 
function, pain and general health of cervical 
cancer are the lowest among the other 
diagnosa. However, the other diagnosa of 
cancer have the lowest score of fatigue and 
emotional function. This result show that the 
SF-36 could be given to in various cancer 
patients. The results are different to the study 
from the previous study in China, which 
suggested that in different groups of age and 
gender, the score of SF-36 dimensions were 
different as well (Hoopman et al., 2009, Li et al., 
2003). In this study, the gender and age were 
not taken into account as known-group validity, 
because the small sample size of opposite 
group. 
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Table III shows the discriminant and 
convergent validity of all questions in SF-36. 
All of the questions met the convergent 
validity, except for questions number 26, 28, 30 
(emotional function), and question no 32 
(social function).  This study suggested that the 
questions which did not meet the convergent 
validity had low correlation with their domain. 
Thus the questions should be constructed so 
that each questions in one domain have closely 
meaning which more represent the emotional 
function. The other plausible explanation is 
because the subjects have some problems            
in translating the questions into what they         
were exactly feel. The  previous study  in  China  
population also showed that the questions in 
social function had low correlation with their 
domain (Li et al., 2003). The social domain only 
had two questions and one of them is more 
correlated with the other domain. Thus, the 
question should be constructed so that the 
subject will  easier to understand and to 
translate the question into their daily activity.  
According to the discriminant validity, 
the question number 28 (emotional function) is 
more correlated with fatigue. This result is 
supported with the previous study in China (Li 
et al., 2003). This finding showed that the 
downhearted and blue feeling are translated 
into   the   fatigue   condition   by  the  subjects.  
Table I. Subject’s characteristics (n=203) 
 
Characteristics   
Age (Mean ± SD) 48.3 ± 9.4  
Indeks Karnofsky  (Mean ± SD) 82.3 ± 7.1  
 Number % 
Gender 
   Male 
   Female 
 
   13 
190 
 
   6.4 
93.6 
Education (n=201) 
   No schooling 
   Elementary 
   High School 
   Undergraduate 
 
   68 
   55 
   65 
   13 
 
33.8 
27.4 
32.3 
   6.5 
Diagnosa of cancer 
   cervix 
   ovarium 
   others 
 
122 
   53 
   28 
 
60.1 
26.1 
13.8 
 
Table II. Known-group validity 
 
 Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Mean 
±SD 
Type of Cancer PF RPF REF F EF SF P GH 
Cervical  59.5± 
27.3 
27.3± 
39.5 
32.2± 
43.3 
59.7± 
18.3 
63.8± 
22.6 
52.7± 
23.3 
55.4± 
27.5 
50.7± 
13.8 
Ovarium 60.3± 
26.7 
33.5± 
43.3 
32.7± 
44.1 
79.4± 
110.3 
64.6± 
22.6 
52.6± 
20.0 
63.3± 
29.2 
52.7± 
17.7 
Others 62.7± 
28.1 
29.9± 
43.8 
36.9± 
45.5 
57.9± 
19.9 
60.9± 
22.2 
57.5± 
19.1 
58.5± 
26.7 
51.0± 
11.5 
P value 0.88 0.65 0.88 0.10 0.76 0.55 0.23 0.68 
 
PF: Physical Function; RPF: Role limitation because of Physical problem; REF: Role limitation because of 
Emotional problem, F: Fatigue; EF: Emotional Function; SF: Social Function; P: Pain; GH: General Health 
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Table III. Discriminant and convergent validity 
 
 
Physical 
function 
Limited 
role due to 
emotional 
problem 
Limited 
role due to 
emotional 
problem 
Fatigue 
Emotional 
function 
Social 
function 
Pain 
General 
health 
1 0.08 0.13 0.07 0.06 -0.001 0.05 0.08 0.30 
2 0.12 0.12 0.15 0.083 0.042 0.10 0.10 0.40 
3 0.50 0.36 0.40 0.08 0.21 0.12 0.01 0.10 
4 0.58 0.30 0.35 0.073 0.03 0.29 0.10 0.17 
5 0.62 0.17 0.25 0.02 0.32 0.23 0.22 0.31 
6 073 0.01 0.06 0.02 0.38 0.26 0.23 0.27 
7 0.76 0.04 0.03 0.05 0.44 0.26 0.27 0.33 
8 0.65 0.08 0.02 0.01 0.49 0.20 0.27 0.34 
9 0.05 0.27 0.36 0.00 0.04 0.29 0.14 0.06 
10 0.76 0.13 0.23 0.02 0.31 0.34 0.31 0.32 
11 0.76 0.07 0.17 0.02 0.37 0.30 0.29 0.33 
12 0.40 0.20 0.01 0.01 0.36 0.08 0.14 0.21 
13 0.14 0.73 0.63 0.05 0.36 0.09 0.02 0.08 
14 0.16 0.79 0.76 0.03 0.13 0.15 0.10 0.01 
15 0.17 0.77 0.66 0.12 0.18 0.09 0.06 0.04 
16 0.16 0.77 0.67 0.02 0.15 0.12 0.05 0.01 
17 0.24 0.69 0.76 0.02 0.22 0.23 0.06 0.01 
18 0.18 0.70 0.76 0.03 0.11 0.18 0.11 0.04 
19 0.19 0.71 0.78 0.03 0.08 0.23 0.10 0.03 
20 0.17 0.15 0.17 0.04 0.03 0.75 0.22 0.04 
21 0.25 0.04 0.06 0.02 0.30 0.20 0.84 0.27 
22 0.24 0.02 0.03 0.02 0.28 0.31 0.78 0.28 
23 0.09 0.08 0.02 0.40 0.10 0.04 0.18 0.21 
24 0.21 0.20 0.14 0.09 0.75 0.18 0.23 0.24 
25 0.28 0.36 0.26 0.04 0.80 0.06 0.20 0.30 
26 0.07 0.02 0.02 0.03 0.24 0.09 0.02 0.05 
27 0.40 0.74 0.80 0.59 0.01 0.90 0.71 0.48 
28 0,20 0.16 0.23 0.28* 0.20 0.22 0.21 0.22 
29 0.24 0.18 0.11 0.40 0.75 0.16 0.19 0.32 
30 0.18 0.14 0.13 0.27 0.35 0.25 0.21 0.29 
31 0.02 0.05 0.03 0.42 0.15 0.03 0.08 0.31 
32 0.29 0.07 0.06 0.24 0.38* 0.13 0.17 0.37 
33 0.40 0.08 0.20 0.08 0.17 0.74 0.15 0.40 
34 0.18 0.10 0.04 0.05 0.46 0.07 0.22 0.51 
35 0.12 0.15 0.12 0.13 0.15 0.05 0.05 0.45 
36 0.32 0.33 0.23 0.01 0.74 0.08 0.24 0.42 
 
The numbers in the box indicated significant correlation of questions with their domain. The number with* 
indicated the questions which did not meet the criteria of discriminant validity. 
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The question number 2 of social function is 
also more correlated with the emotional 
function, meaning that the subjects had 
problem to translate the impact of physical and 
emotional problem into their social activity. 
The last analysis is the factor analysis of 
all questions in SF-36 questionnaire. According 
to the KMO and Bartlett test, the data was 
suitable for factor analysis with KMO value 
was 0.843 and Bartlett test was 5.46 x 103, P = 
0.000). The extraction of factors was based on 
the criterion of an eigenvalue greater than one 
that is nine-factor solution with 72.92% of total 
variance. All of the questions are loaded 
significantly in one factor. The interesting point 
in our finding is some questions are loaded 
together with the other questions in different 
domains. For instance; question number 3 are 
loaded together with questions which are 
correlated physical problem and emotional 
problem domains in factor 2. Furthermore 
some questions which are related with 
emotional, social, fatigue and general health 
domains are also loaded together with 
questions in physical function (data was not 
shown). This finding supported the previous 
finding that subjects could be have some 
difficulties in translating the questions into their 
real condition. Most of the questions are 
translated into physical condition because they 
did not aware of emotional, social and fatigue 
functions. 
This study was conducted in cancer 
subjects who might have more depressed 
condition due to their disease or treatment than 
the other disease. Therefore the future studies 
on developing the Indonesian version of SF-36 
scales are  still needed. 
 
CONCLUSION 
The development of Indonesian version 
of SF-36 scales in cancer disease is still less 
satisfactory. According to the result of this 
study, most of the questions in this version 
should be reconstructed.  
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